FoxP3 and indoleamine 2,3-dioxygenase immunoreactivity in sentinel nodes from melanoma patients

Ryan, Marisa A.; Crow, Jennifer; Kahmke, Russel; Fisher, Samuel R.; Su, Zuowei; Lee, Walter T.

doi:10.1016/j.amjoto.2014.08.009

Cited by 14 publications

(10 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…25 In addition, sentinel lymph node positivity and poor outcome are associated with FoxP3/IDO immunoreactivity, and it has been suggested that, even in melanoma patients with uninvolved sentinel nodes, IDO could be considered an independent predictive marker. 23,27,28 To our knowledge, one previously published study supports the view that low Trp concentrations and high Kyn/Trp and neopterin concentrations in serum predict shorter overall survival in melanoma. 26 This is not the case in other types of cancers in which the clinical significance of IDO has often been analysed in serum samples 19,29 In this work, we demonstrate for the first time a clear association between serum IDO activity and all stages of melanoma.…”

Section: Discussionsupporting

confidence: 57%

“…Specifically, it has been described that high immunohistochemical expression of IDO in melanoma lymph node metastases is associated with more FoxP3‐expressing regulatory T cells and shorter survival . In addition, sentinel lymph node positivity and poor outcome are associated with FoxP3/IDO immunoreactivity, and it has been suggested that, even in melanoma patients with uninvolved sentinel nodes, IDO could be considered an independent predictive marker …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Indoleamine 2,3 dioxygenase as a prognostic and follow‐up marker in melanoma. A comparative study with LDH and S100B

Lecea

Palomares

Kassam

et al. 2016

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 57%

Section: Discussionmentioning

confidence: 99%

Indoleamine 2,3 dioxygenase as a prognostic and follow‐up marker in melanoma. A comparative study with LDH and S100B

Lecea

Palomares

Kassam

et al. 2016

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…[24] This immunosuppression occurs even in the absence of sentinel-node involvement[25], suggesting that it may be partly mediated by the release of different cytokines from the primary tumor. [26–29]…”

Section: Discussionmentioning

confidence: 99%

Effect of time to sentinel-node biopsy on the prognosis of cutaneous melanoma

Tejera‐Vaquerizo

Nagore

Puig

et al. 2015

European Journal of Cancer

View full text Add to dashboard Cite

Instroduction In patients with primary cutaneous melanoma, there is generally a delay between excisional biopsy of the primary tumor and sentinel-node biopsy. The objective of this study is to analyze the prognostic implications of this delay. Patients and method This was an observational, retrospective, cohort study in four tertiary referral hospitals. A total of 1963 patients were included. The factor of interest was the interval between the date of the excisional biopsy of the primary melanoma and the date of the sentinel-node biopsy (delay time) in the prognosis. The primary outcome was melanoma-specific survival and disease-free survival. Results A delay time of 40 days or less (HR, 1.7; CI, 1.2 to 2.5) increased Breslow thickness (Breslow ≥2 mm, HR >3.7; CI 1.4 to 10.7), ulceration (HR 1.6; CI, 1.1 to 2.3), sentinel-node metastasis (HR, 2.9; CI, 1.9 to 4.2), and primary melanoma localized in the head or neck were independently associated with worse melanoma-specific survival (all P<0.03). The stratified analysis showed that the effect of delay time was at the expense of the patients with a negative sentinel-node biopsy and without regression. Conclusion Early sentinel-node biopsy is associated with worse survival in patients with cutaneous melanoma.

show abstract

“…For these patients, outcomes after prompt removal of NSLN via CLND are less clear. Models incorporating histologic (SLN microscopic tumor burden) and immunologic criteria (relative tumor-infiltrating and regulatory T lymphocyte function) may help guide future prospective studies in predicting nodal recurrence and systemic disease [40•, 41–43]. Presently, patients with suspected NSLN disease that remains isolated to the regional nodal basin may continue to be candidates for CLND.…”

Section: Discussionmentioning

confidence: 99%

Sentinel Lymph Node Biopsy and Completion Lymph Node Dissection for Melanoma

Masoud

Perone

Farrow

et al. 2018

Curr. Treat. Options in Oncol.

View full text Add to dashboard Cite

This review critically evaluates recent trials which have challenged the practice of completion lymph node dissection (CLND) for melanoma patients diagnosed with regional metastasis by positive sentinel lymph node biopsy (SLNB). Two trials in the last 2 years, DeCOG-SLT and MSLT-II, found no significant differences in melanoma-specific survival between patients, whether they received immediate CLND or observation after positive SLNB, despite decreases in nodal recurrence achieved by dissection. These trials together disfavor routine CLND in most patients after positive SLNB. However, their conclusions are limited by study populations which overall harbored a lower burden of SLN disease. Special attention needs to be given to patients who do have higher risk disease, with SLN tumor burdens exceeding 1 mm in diameter, for whom CLND may remain both prognostic and therapeutic. Current guidelines thus recommend either CLND or careful observation after positive SLNB after appropriate risk stratification of patients. While a decline in CLND is inevitable, treatment of stage III melanoma is witnessing the concurrent rise of effective adjuvant therapies. PD-1 inhibitors such as nivolumab, or combination BRAF/MEK inhibitors for V600E or K mutant melanoma, which were previously available to only trial patients with completely resected stage III disease, are now approved for use in patients with positive SLNB alone. Providers are better equipped than ever to treat clinically occult, regional metastatic disease with SLNB followed by adjuvant therapy for most patients, but should take steps to avoid undertreatment of high-risk patients who may proceed to disease relapse or progression.

show abstract

FoxP3 and indoleamine 2,3-dioxygenase immunoreactivity in sentinel nodes from melanoma patients

Cited by 14 publications

References 33 publications

Indoleamine 2,3 dioxygenase as a prognostic and follow‐up marker in melanoma. A comparative study with LDH and S100B

Indoleamine 2,3 dioxygenase as a prognostic and follow‐up marker in melanoma. A comparative study with LDH and S100B

Effect of time to sentinel-node biopsy on the prognosis of cutaneous melanoma

Sentinel Lymph Node Biopsy and Completion Lymph Node Dissection for Melanoma

Contact Info

Product

Resources

About